Analyst firms · Leerink Partners · PFE
Leerink Partners PFE price target and rating history
Pfizer Inc. (PFE) · Health Care
Leerink Partners rates Pfizer Inc. (PFE) Mkt Perform with a $55 price target, as of its latest action on May 23, 2022. It has published 5 rating actions on PFE since July 2021, including 0 upgrades and 0 downgrades. Across 7 firms with a PFE price target in the last 12 months, the median target is $26.
- Current rating
- Mkt Perform
- Price target
- $55
- Median target, all firms
- $26
- Actions on PFE
- 5
Leerink Partners price target on PFE
Every Leerink Partners rating on PFE
- May 23, 2022
- Dec 15, 2021
- Nov 3, 2021
- Sep 20, 2021
- Jul 29, 2021
How other firms rate PFE
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| DZ Bank | Hold | Nov 6, 2026 | |
| HSBC | Hold | $28 | Jul 6, 2026 |
| RBC Capital Markets | Sector Perform | $25 | Jun 10, 2026 |
| Argus Research | Buy | $35 | Mar 2, 2026 |
| Barclays | Underweight | $25 | Feb 20, 2026 |
| Daiwa | Neutral | $27 | Feb 12, 2026 |
| UBS | Neutral | $25 | Jan 7, 2026 |
| Citigroup | Neutral | $26 | Dec 2, 2025 |
Questions about Leerink Partners and PFE
- What is Leerink Partners's price target for PFE?
- Leerink Partners's latest stated price target for Pfizer Inc. (PFE) is $55, from its action on May 23, 2022.
- What is Leerink Partners's rating on PFE?
- Leerink Partners rates PFE Mkt Perform, a neutral rating, as of May 23, 2022.
- When did Leerink Partners last change its view on PFE?
- On May 23, 2022, Leerink Partners starts coverage at Mkt Perform, price target $55.
- How does Leerink Partners's PFE target compare with other analysts?
- Across 7 firms with a PFE price target in the last 12 months, the median target is $26.
More PFE rating histories
All Leerink Partners ratingsPFE news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.